Edwards Lifesciences exec sells 619 shares

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) executive Daniel J. Lippis, Corporate Vice President for TAVR, exercised employee stock options covering 619 shares of common stock at an exercise price of $72.68 per share on September 11, 2026, then sold 619 shares at $87.51 per share the same day under a Rule 10b5-1 trading plan. Following the option exercise, he held 3,714 options on Edwards Lifesciences common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 619 shares ($9K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Lippis Daniel J.

Role CVP, TAVR

Sold 619 shs ($54K)

Approx. gross sale proceeds $54K

Approx. exercise cost $45K

Approx. pre-tax spread $9K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	619	$0.00	$0.00
Exercise	Common Stock F1	619	$72.68	$45K
Sale	Common Stock F1	619	$87.51	$54K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 3,714 contracts (Direct); Common Stock — 40,033.9103 shares (Direct)

Footnotes (1)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

Key Figures

Options exercised: 619 shares Exercise price: $72.68 per share Shares sold: 619 shares +4 more

7 metrics

Options exercised 619 shares Employee stock options exercised for common stock on September 11, 2026

Exercise price $72.68 per share Exercise price of employee stock options on September 11, 2026

Shares sold 619 shares Common shares sold on September 11, 2026

Sale price $87.51 per share Price for sale of common shares on September 11, 2026

Remaining options 3,714 options Options on Edwards Lifesciences common stock held after the exercise

Rule 10b5-1 plan adoption date February 13, 2026 Adoption date of the trading plan covering the reported transactions

Option expiration date May 6, 2027 Expiration date of the exercised employee stock option grant

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option, beneficial ownership

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option financial

"Employee Stock Option (Right to Acquire)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

beneficial ownership financial

"This Form 4 reflects changes in beneficial ownership only"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did EW executive Daniel J. Lippis report in this Form 4?

Daniel J. Lippis reported exercising employee stock options for 619 shares of Edwards Lifesciences common stock at $72.68 per share and selling 619 shares at $87.51 per share on September 11, 2026, under a Rule 10b5-1 trading plan.

How many Edwards Lifesciences (EW) options did Daniel J. Lippis retain after the transactions?

After exercising the options on September 11, 2026, Daniel J. Lippis held 3,714 options on Edwards Lifesciences common stock, as reported in the filing.

At what prices did Daniel J. Lippis exercise and sell EW shares?

The employee stock options were exercised at an exercise price of $72.68 per share, and the resulting 619 shares of Edwards Lifesciences common stock were sold at $87.51 per share on September 11, 2026.

Were Daniel J. Lippis’s EW transactions under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported transactions were effected under a Rule 10b5-1 trading plan adopted by Daniel J. Lippis on February 13, 2026.

What role does Daniel J. Lippis hold at Edwards Lifesciences (EW)?

Daniel J. Lippis is identified in the filing as a Corporate Vice President, TAVR at Edwards Lifesciences Corp.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 07:15 PM EDT Accepted by SEC EDGAR 09/11/2026 - 07:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		M(1)		619	A	$72.68	40,652.9103	D
Common Stock	09/11/2026		S(1)		619	D	$87.51	40,033.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$72.68	09/11/2026		M			619	05/07/2021	05/06/2027	Common Stock	619	$0.0000	3,714	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)